http://www.hopkinscme.org/ofp/eCysticFibrosisReview/Timely commentary on current research, best practices and clinical management issues, provided by an expert panel of Cystic Fibrosis Specialistsen-ushttp://www.hopkinscme.org/ofp/eCysticFibrosisReview/http://www.dkbmedstream.com/podcast/eCF/ecysticfibrosis.jpg144144Conversations with key opinion leaders in the field of Cystic Fibrosis.© 2008 JHUSOM and eCysticFibrosis ReviewSun, 11 Dec 2011 11:40:39 PSTFeedForAll Mac v2.1 (2.1.0.1); http://www.FeedForAll.com/A bi-monthly review of journal literature by key topics, with access to available abstracts and full text articlesTimely commentary on current research, best practices and clinical management issues, provided by an expert panel of Cystic Fibrosis SpecialistsCystic,Fibrosis,CMEeCysticFibrosis Reviewno© 2008 JHUSOM and eCysticFibrosis ReviewCystic,Fibrosis,CMEScience & Medicine/Medicinenews@customerparadigm.comeCysticFibrosis Reviewhttp://feedproxy.google.com/~r/eCysticFibrosis/~3/x2BTyF4C0rw/0412.htmlSciencenews@customerparadigm.com (eCysticFibrosis Review)http://www.hopkinscme.edu/ofp/eCysticFibrosisReview/newsletters/2012/0412.htmlNutritional status has long been identified as a strong predictor of outcomes in patients with CF and has been the focus of many quality improvement efforts in CF care. Many factors contribute to high caloric demands in patients with CF, including inefficiencies in digestion and absorption of nutrients, increased work of breathing, and a chronic inflammatory state. The high number of daily calories required to maintain nutritional goals adds to the burden of care for both patients and their families. In this issue, Dr. Elizabeth Yen reviews new research highlighting the strong positive impact of early behavioral and nutritional education. Exploring predictors of long-term response to such interventions she discusss how body image may affect compliance with nutritional recommendations in adolescents; and, then present data describing positive outcomes with gastrostomy tube placement for supplemental enteral intake.<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/x2BTyF4C0rw" height="1" width="1"/>http://www.hopkinscme.edu/ofp/eCysticFibrosisReview/newsletters/2012/0412.htmlhttp://feedproxy.google.com/~r/eCysticFibrosis/~3/YQsyMSSIqiM/eCF_March2012_podcast.mp3Sciencenews@customerparadigm.com (eCysticFibrosis Review)Mon, 02 Jan 2012 05:00:00 PSThttp://www.dkbmedstream.com/podcast/eCF/eCF_March2012_podcast.mp3Featured Cases: The Role of Exercise and Physical Activity in Optimizing Outcomes Among Patients with CF<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/YQsyMSSIqiM" height="1" width="1"/>Exercise and Physical ActivityThe Role of Exercise and Physical Activity00:29:19cystic fibrosis, CF lung disease, CFTR, CFTR modifiers, genetic modifiers, environmental modifiers, biofilm testing, airway infection, genome, lung disease severityeCysticFibrosis Reviewnohttp://www.dkbmedstream.com/podcast/eCF/eCF_March2012_podcast.mp3http://www.dkbmedstream.com/podcast/eCF/eCF_March2012_podcast.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/6QA09Pf-tFI/eCF_January2012_podcast.mp3Sciencenews@customerparadigm.com (eCysticFibrosis Review)Mon, 02 Jan 2012 05:00:00 PSThttp://www.dkbmedstream.com/podcast/eCF/eCF_January2012_podcast.mp3Case studies offer opportunity to differentiate the needs to treat patients with CF to genotype and phenotype. The introduction begins with describing the factors that contribute to differences in severity of CF. Equally important is to identify environmental modifiers that can be manipulated to alter outcome in CF; ultimately we recognize when and how genetic testing for CFTR and for modifier genes may be best used in patient management.<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/6QA09Pf-tFI" height="1" width="1"/>Modifiers of CF Lung DiseaseDrs. Cutting and Collaco will help expand our understanding of the genotypic and phenotypic modifiers in the treatment of cystic fibrosis, with the discussion some typical case scenarios.00:29:29cystic fibrosis, CF lung disease, CFTR, CFTR modifiers, genetic modifiers, environmental modifiers, biofilm testing, airway infection, genome, lung disease severityeCysticFibrosis Reviewnohttp://www.dkbmedstream.com/podcast/eCF/eCF_January2012_podcast.mp3http://www.dkbmedstream.com/podcast/eCF/eCF_January2012_podcast.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/iy3s1TFAN_Y/ecf_11_11.mp3Sciencenews@customerparadigm.com (eCysticFibrosis Review)Wed, 02 Oct 2002 06:00:00 PDThttp://www.dkbmedstream.com/podcast/eCF/ecf_11_11.mp3This podcast has been developed for clinicians caring for patients with issues related to cystic fibrosis. You can also read the companion newsletter. In this edition Dr. Chris Goss will explain the use of new inhalation therapies for the treatment of cystic fibrosis, with the discussion some typical case scenarios. The discussion will include the current clinical definition of an acute pulmonary exacerbation in CF, describe the current approach to the treatment of an acute pulmonary exacerbation, and explain the complexities of assessing antimicrobial resistance patterns via sputum isolates in patients with cystic fibrosis.<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/iy3s1TFAN_Y" height="1" width="1"/>In this edition Dr. Chris Goss will explain the use of new inhalation therapies for the treatment of cystic fibrosis, with the discussion some typical case scenarios. This podcast has been developed for clinicians caring for patients with issues related to cystic fibrosis. You can also read the companion newsletter. In this edition Dr. Chris Goss will explain the use of new inhalation therapies for the treatment of cystic fibrosis, with the discussion some typical case scenarios.00:29:10cystic fibrosis, acute pulmonary exacerbation, antimicrobial resistance patterns, lung function, genotype delta F508 homozygous, Pseudomonas aeruginosa, Staphylococcus aureus, spirometry, airway clearance, pneumothorax, antibioticseCysticFibrosis Reviewnohttp://www.dkbmedstream.com/podcast/eCF/ecf_11_11.mp3http://www.dkbmedstream.com/podcast/eCF/ecf_11_11.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/-TMwsMl-Ehw/November10_eCF_podcast.mp3Sciencenews@customerparadigm.com (eCysticFibrosis Review)Mon, 04 Jan 2010 15:59:33 PSThttp://www.dkbmedstream.com/podcast/eCF/November10_eCF_podcast.mp3Featured Cases: New Inhalation Therapies<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/-TMwsMl-Ehw" height="1" width="1"/>A clinical discussion of Emerging Pathogens in Cystic Fibrosis. More info at eCysticFibrosisReview.org.The eCysticFibrosis Review podcast is a clinical discussion between our November authors, Michael Boyle, MD, Elliott Dasenbrook, MD and Robert Busker, eCysticFibrosis Reviews Medical Editor. The topic is Emerging Pathogens in Cystic Fibrosis. Participants can now receive 0.5 credits per podcast after completing an online post-test via the links provided on the website page, eCysticFibrosisReview.org31:31infection, control, MRSA, antibiotic-resistant, Pseudomonas, aeruginosaeCysticFibrosis Reviewnohttp://www.dkbmedstream.com/podcast/eCF/November10_eCF_podcast.mp3http://www.dkbmedstream.com/podcast/eCF/November10_eCF_podcast.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/4sb4Dl22XpI/Sciencenews@customerparadigm.com (eCysticFibrosis Review)Sun, 03 Oct 2010 16:26:35 PDT1708D07F-E770-49BD-A88B-6FD75585DB71-864-00001321CDB75848-FFAAfter participating in this podcast activity the participant will demonstrate the ability to:<br /> Describe the assessment process for infants diagnosed with cystic fibrosis,<br /> Explain the use of chronic daily therapies for adolescents with CF, and<br /> Discuss the treatment of pulmonary exacerbations in adult CF patients.<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/4sb4Dl22XpI" height="1" width="1"/>Participants in this podcast will: Describe the assessment process for infants diagnosed with cystic fibrosis, Explain the use of chronic daily therapies for adolescents with CF, and Discuss the treatment of pulmonary exacerbations in adult CF patients.Clinical practice guidelines have become a regular component of health care. The Cystic Fibrosis Foundation has supported the development of several recent clinical practice guidelines to review the evidence that endorses many of the therapies currently in use. Although numerous clinical manifestations of cystic fibrosis (CF) exist, the principal causes of disease-related morbidity and mortality are due to pancreatic insufficiency and chronic airway infection. Recommendations are now available on the assessment and treatment of nutritional disease, use of airway clearance therapies, and use of chronic medications to maintain lung health. Acute complications of CF lung disease include pulmonary exacerbations, hemoptysis, and pneumothorax; guidelines on the management of these complications are currently available as well. Finally, as newborn screening for CF has become standard in all states, we can expect that most patients will be diagnosed in the absence of symptoms. Infant care guidelines should provide primary care physicians with the information needed for appropriate assessment and treatment of newly diagnosed patients. In this podcast recording, Dr. Patrick Flume utilizes patient cases to summarize the clinical practice guidelines for individuals with CF, to aid clinicians in improving the quality and consistency of the care they provide.00:41:04cystic fibrosis, elevated immunoreactive trypsinogen, delta-F508, newborn screening, pancreatic insufficiency, airway clearance therapy, oropharyngeal cultures, Pseudomonas aeruginosa, ELITE trial, chest physiotherapy, PEP therapy devices, inhaled tobramyeCysticFibrosis Reviewnohttp://ecysticfibrosisreview.org/http://www.dkbmedstream.com/podcast/eCF/September10_eCF_podcast.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/4sb4Dl22XpI/Science and Medicinenews@customerparadigm.com (eCysticFibrosis Review)Sun, 11 Jul 2010 20:14:24 PDT39106DB7-B08A-405F-8ACA-382A8082EE01-450-00000DB1BDF8B9B2-FFAPatients with cystic fibrosis are living longer, so they are developing more complications, such as bone disease, and insuring that vitamin D supplementation is adequate and figuring out new ways to prevent bone disease is becoming more and more important for CF patients. The discussion today will focus on the basis of the current vitamin D recommendation for patients with cystic fibrosis, describe the potential for success of various strategies for treatment of vitamin D insufficiency, and compare the potential benefits and risks of using bisphosphonates for the treatment of osteoporosis in patients with cystic fibrosis.<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/4sb4Dl22XpI" height="1" width="1"/>Patients with cystic fibrosis are living longer so they are developing more complications, insuring that vitamin D supplementation is adequate and figuring out new ways to prevent bone disease is becoming more and more important for CF patients.In 2002, the CF Foundation convened a consensus conference. This consensus conference developed specific recommendations for the prevention of bone disease and the optimal supplementation of vitamin D for patients with cystic fibrosis. The original consensus guidelines did not have any actual demonstration in cystic fibrosis patients, and most of this was expert opinion. And at this time we are actually trying to test these guidelines to see if they hold true in those with cystic fibrosis. Since patients with cystic fibrosis are living longer, they are developing more complications, such as bone disease, and insuring that vitamin D supplementation is adequate and figuring out new ways to prevent bone disease is becoming more and more important for CF patients. In the discussion today, Peter Mogayzel, MD & Dianna Green, MD, of the Johns Hopkins University School of Medicine, will focus on the basis of the current vitamin D recommendation for patients with cystic fibrosis, describe the potential for success of various strategies for treatment of vitamin D insufficiency, and compare the potential benefits and risks of using bisphosphonates for the treatment of osteoporosis in patients with cystic fibrosis.26:2925-hydroxy vitamin D, ergocalciferol, cholecalciferol, ultraviolet B, sunlight, vitamin D deficiency, vitamin D supplementation, CF Foundation guidelines, cystic fibrosis, bone disease, bone health, weight gain, vitamin supplement, fat soluble, internatioeCysticFibrosis Reviewnohttp://ecysticfibrosisreview.org/http://www.dkbmedstream.com/podcast/eCF/July10_eCF_podcast.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/0ltcgDr2S84/Science and Medicinenews@customerparadigm.com (eCysticFibrosis Review)Fri, 15 Jan 2010 13:51:19 PST63C89D33-92FE-46D6-9459-5E3136A5E230-199-000000D7CCA6422E-FFAToni Moran, MD discusses how diagnostic criteria were chosen for cystic fibrosis-related diabetes, describes the appropriate screening test for diabetes and CF, and explains the evidence basis for insulin as an accepted therapy for CFRD.<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/0ltcgDr2S84" height="1" width="1"/>Toni Moran, MD discusses how diagnostic criteria were chosen for cystic fibrosis-related diabetes, describes the appropriate screening test for diabetes and CF, and explains the evidence basis for insulin as an accepted therapy for CFRD.In September of 2009, the Cystic Fibrosis Foundation held a third CFRD consensus conference, co-sponsored by the American Diabetes Association and the Lawson Wilkins Pediatric Endocrine Society, providing a new set of recommendations for treating cystic fibrosis-related diabetes. Johns Hopkins provided evidence review so there can be evidence-based guidelines. Diagnostic & treatment criteria are presented in this podcast.30:00CF-related diabetes, type 1 diabetes, type 2 diabetes, hemoglobin-A1c, glucose tolerance test, Cystic Fibrosis Foundation, American Diabetes Association, Lawson Wilkins Pediatric Endocrine Society, cystic fibrosiseCysticFibrosis Reviewnohttp://www.ecysticfibrosisreview.org/http://www.dkbmedstream.com/podcast/eCF/January10_eCF_podcast.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/0ltcgDr2S84/Sciencenews@customerparadigm.com (eCysticFibrosis Review)Fri, 15 Jan 2010 13:45:32 PST1130B165-A186-42A0-A16F-C084FFC7F5D0-416-00000DFC45758DA7-FFAA clinical discussion of Measurement of Early Lung Disease in Children With Cystic Fibrosis. More info at eCysticFibrosisReview.org<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/0ltcgDr2S84" height="1" width="1"/>A clinical discussion of Measurement of Early Lung Disease in Children With Cystic Fibrosis. More info at eCysticFibrosisReview.orgThe eCysticFibrosis Review podcast is a clinical discussion between our January authors, Stephanie D. Davis, MD, Jessica Pittman, MD and Robert Busker, eCysticFibrosis Reviews Medical Editor. The topic is Measurement of Early Lung Disease in Children With Cystic Fibrosis. Participants can now receive 0.5 credits per podcast after completing an online post-test via the links provided on this page via eCysticFibrosisReview.org26:18physiologic, structural, measurements, preschool, pulmonary, function, testingeCysticFibrosis Reviewnohttp://www.ecysticfibrosisreview.org/http://www.dkbmedstream.com/podcast/eCF/January09_eCF_podcast.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/0ltcgDr2S84/Sciencenews@customerparadigm.com (eCysticFibrosis Review)Fri, 15 Jan 2010 13:45:36 PST526577D7-E507-4E9E-883B-B5E77BA65306-416-00000E0C612E589C-FFAA clinical discussion of Emerging Pathogens in Cystic Fibrosis. More info at eCysticFibrosisReview.org.<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/0ltcgDr2S84" height="1" width="1"/>A clinical discussion of Emerging Pathogens in Cystic Fibrosis. More info at eCysticFibrosisReview.org.The eCysticFibrosis Review podcast is a clinical discussion between our November authors, Michael Boyle, MD, Elliott Dasenbrook, MD and Robert Busker, eCysticFibrosis Reviews Medical Editor. The topic is Emerging Pathogens in Cystic Fibrosis. Participants can now receive 0.5 credits per podcast after completing an online post-test via the links provided on the website page, eCysticFibrosisReview.org31:31infection, control, MRSA, antibiotic-resistant, Pseudomonas, aeruginosaeCysticFibrosis Reviewnohttp://www.ecysticfibrosisreview.org/http://www.dkbmedstream.com/podcast/eCF/November08_eCF_podcast.mp3http://feedproxy.google.com/~r/eCysticFibrosis/~3/0ltcgDr2S84/Sciencenews@customerparadigm.com (eCysticFibrosis Review)Fri, 15 Jan 2010 13:45:42 PSTDF66D33B-0992-4EBA-9973-C3AC3D87B18E-416-00000E2247CFB6E1-FFAThe eCysticFibrosis Review podcast is a clinical discussion between our September authors, Garry Cutting, MD, Barbara Karczeski, MS and Robert Busker, eCysticFibrosis Reviews Medical Editor. The topic is How to Interpret Genetic Testing for Cystic Fibrosis. Participants can now receive 0.5 credits per podcast after completing an online post-test via the links provided on the website page, eCysticFibrosisReview.org<img src="http://feeds.feedburner.com/~r/eCysticFibrosis/~4/0ltcgDr2S84" height="1" width="1"/>How to Interpret Genetic Testing for Cystic Fibrosis. Participants can now receive 0.5 credits per podcast after completing an online post-test via the links provided on the website page, eCysticFibrosisReview.orgThe eCysticFibrosis Review podcast is a clinical discussion between our September authors, Garry Cutting, MD, Barbara Karczeski, MS and Robert Busker, eCysticFibrosis Reviews Medical Editor. The topic is How to Interpret Genetic Testing for Cystic Fibrosis. Participants can now receive 0.5 credits per podcast after completing an online post-test via the links provided on the website page, eCysticFibrosisReview.org31:31transmitting genetic information, genetic mutations, genetic testing in new born CF screening, Garry Cutting, MD, cystic fibrosis transmembrane conductance regulator, CFTR geneeCysticFibrosis Reviewnohttp://www.ecysticfibrosisreview.org/http://www.dkbmedstream.com/podcast/eCF/September07_eCF_podcast.mp3eCysticFibrosis ReviewnonadultA bi-monthly review of journal literature by key topics, with access to available abstracts and full text articles